Chemotherapy: Pemetrexed

Phase 2Small molecule

Johnson & Johnson

Chemotherapy: Pemetrexed is one of 57 small molecule programs targeting Glioblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlioblastomaActive, not recruiting

KRAS G12C MutationRecruiting

GlioblastomaPhase 2

Active, not recruiting

KRAS G12C MutationPhase 1

Recruiting

Competition

Competitive Landscape

132 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

58 2

Keytruda

Merck & Co.

Phase 3

20 3

Opdivo

Bristol-Myers Squibb

Phase 3

19 4

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Yervoy

12 6

Ceenu

AAzurity Pharmaceuticals

Phase 3

22 7

Antabuse

Teva

Phase 3

5 8

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 9

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 10

Libtayo

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

KRAS G12C Mutation

NCT06946927

PreclinicalActive, not recruiting

Glioblastoma

NCT04528680

Q4 2030

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076

Clinical

Trials by Indication[1]

KRAS G12C Mutation1 trial

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting·JJemincare·Phase 1·NCT06946927·72 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT06667076·480 enrolled

Glioblastoma1 trial

Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma

Active, not recruiting·NNorthwestern University·Preclinical·NCT04528680·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Chemotherapy: Pemetrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapy: Pemetrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapy: Pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

Chemotherapy: Pemetrexed

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

KRAS G12C Mutation1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News